[ATHX] Athersys, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.58 Change: 0.04 (2.6%)
Ext. hours: Change: 0 (0%)

chart ATHX

Refresh chart

Description: Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company?s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which has Phase I clinical trials for the patients that have suffered an acute myocardial infarction, and leukemia or other blood-borne cancers; and is ongoing Phase II clinical trials for the patients suffering from inflammatory bowel disease (IBD) and ischemic stroke. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing small pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic

Fundamental Ratios
Shares Outstanding EPS-0.3 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 88.4% Sales Growth - Q/Q211.06% P/E-4.73
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-57.43% ROE-121.38% ROI
Current Ratio2.74 Quick Ratio Long Term Debt/Equity Debt Ratio0.74
Gross Margin Operating Margin-1731.39% Net Profit Margin-1401.34% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities8.32 M Cash From Investing Activities-60 K Cash From Operating Activities1.12 M Gross Profit
Net Profit-12.48 M Operating Profit-6.89 M Total Assets40.19 M Total Current Assets38.73 M
Total Current Liabilities14.15 M Total Debt180 K Total Liabilities21.18 M Total Revenue730 K
Technical Data
High 52 week2.16 Low 52 week1.21 Last close1.36 Last change1.49%
RSI53.13 Average true range0.05 Beta0.54 Volume397.95 K
Simple moving average 20 days-0.44% Simple moving average 50 days0.25% Simple moving average 200 days-10.4%
Performance Data
Performance Week0% Performance Month-8.11% Performance Quart-13.38% Performance Half-3.55%
Performance Year-31.66% Performance Year-to-date-5.56% Volatility daily1.99% Volatility weekly4.45%
Volatility monthly9.11% Volatility yearly31.57% Relative Volume350.71% Average Volume525.08 K
New High New Low


2019-11-14 06:00:00 | Healios Receives Notification of Orphan Designation for Acute Respiratory Distress Syndrome Clinical Program

2019-11-11 09:30:31 | Were Hedge Funds Right About Souring On Athersys, Inc. ATHX?

2019-11-06 16:05:00 | Athersys Reports Third Quarter 2019 Results

2019-11-03 07:47:49 | Did You Manage To Avoid Athersys's NASDAQ:ATHX 36% Share Price Drop?

2019-10-14 13:00:00 | Athersys to Host Third Quarter Financial Results Call

2019-09-25 08:00:00 | Athersys to Present at 2019 Cell & Gene Meeting on the Mesa

2019-09-19 08:37:38 | Athersys, Inc. NASDAQ:ATHX: Is It Growing Too Fast?

2019-09-05 11:22:17 | Edited Transcript of ATHX earnings conference call or presentation 7-Aug-19 8:30pm GMT

2019-08-08 11:23:58 | Athersys ATHX Q2 2019 Earnings Call Transcript

2019-08-07 16:05:00 | Athersys Reports Second Quarter 2019 Results

2019-07-31 14:32:59 | Do Institutions Own Shares In Athersys, Inc. NASDAQ:ATHX?

2019-07-08 11:00:00 | Athersys to Host Second Quarter Financial Results Call

2019-06-20 09:58:57 | Aggie Square executive helps foster university startups

2019-06-04 06:00:00 | Athersys to Present at Jefferies 2019 Healthcare Conference

2019-05-28 06:00:00 | Athersys to Participate in four Events at the International Society of Cell and Gene Therapy Conference

2019-05-24 13:46:47 | Volatility 101: Should Athersys NASDAQ:ATHX Shares Have Dropped 25%?

2019-05-20 12:15:00 | Athersys Presents Data From Its Acute Respiratory Distress Syndrome Clinical Trial at American Thoracic Society International Conference

2019-05-18 09:50:27 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

2019-05-14 15:54:00 | Here's Why Athersys Rose as Much as 15.2% Today

2019-05-09 11:23:53 | Athersys ATHX Q1 2019 Earnings Call Transcript

2019-05-08 21:36:17 | Edited Transcript of ATHX earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-08 16:05:00 | Athersys Reports First Quarter 2019 Results

2019-05-08 14:30:00 | Athersys, Inc. to Host Earnings Call

2019-04-23 16:08:00 | Here's Why Athersys Is Soaring Today

2019-04-23 09:00:01 | Athersys ATHX Upgraded to Strong Buy: Here's What You Should Know

2019-04-23 06:00:00 | HEALIOS K.K. Announces Enrollment of First Patient in Japan in the ONE-BRIDGE Study of MultiStem® Treatment for Acute Respiratory Distress Syndrome

2019-04-15 10:00:00 | Athersys to Host Investor Day in New York City

2019-04-10 14:00:00 | Athersys to Host First Quarter Financial Results Call

2019-03-19 12:03:04 | What Makes Athersys ATHX a New Buy Stock

2019-03-15 17:42:24 | Edited Transcript of ATHX earnings conference call or presentation 14-Mar-19 8:30pm GMT

2019-03-14 19:16:10 | Athersys Inc ATHX Q4 2018 Earnings Conference Call Transcript

2019-03-14 17:04:56 | Athersys Announces Financial Results for Fourth Quarter and Full Year 2018

2019-03-14 14:30:00 | Athersys, Inc. to Host Earnings Call

2019-03-07 08:57:01 | Athersys ATHX Q4 Earnings: What's in Store for the Stock?

2019-02-27 11:04:26 | Is Athersys, Inc.’s NASDAQ:ATHX CEO Paid Enough Relative To Peers?

2019-02-14 08:00:00 | Athersys to Host Year-End 2018 Financial Results Call

2019-01-24 14:20:07 | Athersys' ATHX MultiStem Cell Therapy Succeeds in Study

2019-01-23 09:27:02 | Athersys ATHX Upgraded to Buy: What Does It Mean for the Stock?

2019-01-23 06:00:00 | Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome ARDS

2018-12-17 06:00:00 | Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China

2018-11-13 12:29:57 | Are Athersys Inc’s NASDAQ:ATHX Interest Costs Too High?

2018-11-06 21:15:43 | Edited Transcript of ATHX earnings conference call or presentation 6-Nov-18 9:30pm GMT

2018-11-06 16:05:00 | Athersys Reports Third Quarter 2018 Results

2018-10-29 08:45:00 | Market Trends Toward New Normal in Crown, Athersys, CSX, Magellan Health, Spectrum Brands, and MGIC Investment — Emerging Consolidated Expectations, Analyst Ratings

2018-10-09 16:00:00 | Athersys to Host Third Quarter Financial Results Call

2018-10-08 10:07:02 | Audentes Therapeutics BOLD Catches Eye: Stock Jumps 7%

2018-10-04 15:18:07 | Alnylam Files Clinical Trial Application for ALN-AAT02 in UK

2018-10-03 11:59:03 | Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo

2018-10-02 10:30:00 | Global Stem Cell Market Expected to Reach $270.5 Billion

2018-09-24 06:00:00 | Athersys to Present at 2018 Cell & Gene Meeting on the Mesa